Lv4
640 积分 2024-01-29 加入
CD8+ T cells in the cancer-immunity cycle
8个月前
已完结
Tumor immune evasion through loss of MHC class-I antigen presentation
8个月前
已完结
PD-1/PD-L1 immune checkpoint blockade in ovarian cancer: Dilemmas and opportunities
9个月前
已完结
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer
9个月前
已完结
A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial
9个月前
已完结
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer
9个月前
已完结
Randomized, two‐arm, noncomparative phase 2 study of olaparib plus cediranib or durvalumab in HRR‐mutated, platinum‐resistant ovarian cancer: A substudy of KGOG 3045
9个月前
已完结
皖公网安备34019202002308
